Outcomes after stepwise ablation for persistent atrial fibrillation in patients with heart failure

AbstractBackgroundThere is limited data regarding the outcomes after stepwise ablation for persistent atrial fibrillation (AF) in patients with heart failure (HF).Methods and resultsPatients without structural heart disease undergoing stepwise ablation for persistent AF (continuous AF≤1 year) were studied (n=108; age, 61±10 years) and 32 patients had a history of HF. The HF patients were further grouped on the basis of left ventricular ejection fraction (LVEF)≤45% (n=15) and >45% (n=17). During a median follow-up period of 2.2 years, repeated ablations were necessary in 65 patients. The proportion of patients that were arrhythmia free 1 year after the last ablation was 67% in patients with LVEF≤45%, 86% in LVEF>45%, and 91% in no HF (p=0.0009). In patients with LVEF≤45%, the AF burden was reduced to less than one paroxysmal episode per month, and patients with and without recurrences both showed significant increases in LVEF over the follow-up period (38±7% to 60±10% and 37±6% to 53±10%, respectively).ConclusionsHF patients with LVEF≤45% had lower chances to remain free from arrhythmias after stepwise ablation for persistent AF than those with LVEF>45%. Nevertheless, LVEF also improved in patients with recurrences, reflecting the observed reduction in AF burden and emphasizing the benefits of ablation

QT Interval Revisited —Not Just the Matter of “Interval,” but “Dynamics, Variability and Morphology” Matter!—

Recently, the effects of QT interval prolongation have received more attention among clinicians, industry, and official regulatory agencies. Some have advocated the total elimination or discontinuing development of drugs which prolong the QT interval. In this review, we will give a brief overview of the pathophysiology and the dynamic variability and morphology of the QT interval. From the view point of arrhythmogenesis, QT interval prolongation with increased heterogeneity of ventricular repolarization is critical. The problem is how to detect such an abnormal repolarization. To detect heterogeneity, a new index should be developed and validated, and it must incorporate QT variability and morphology of the T wave. The heart rate correction of the QT interval is also an important issue, and disclosing conflict-corrected QT intervals depend on the formulae used. Not just QT interval prolongation is important; what also matters is the heterogeneity of ventricular repolarization

A case of short-coupled premature ventricular beat-induced ventricular fibrillation with early repolarization in the inferolateral leads

This case report describes a 19-year-old man with early repolarization (ER) in the inferolateral leads and a normal QT interval who survived a cardiac arrest that was likely related to polymorphic ventricular tachycardia (VT). Electrocardiograms (ECGs) also showed unifocal premature ventricular beats (PVBs) with a relatively narrow QRS duration. A Holter ECG documented occasional short-coupled PVBs following non-sustained VTs. Pharmacological stress testing was also performed to assess the effects of anti-arrhythmic drugs on ER (the J wave) and PVBs. We performed successful radiofrequency catheter ablation to prevent the recurrence of ventricular fibrillation after cardioverter-defibrillator implantation

Manifestation of ST-Segment Elevation in Right Precordial Leads during Ischemia at a Right Ventricular Outflow Tract Area in a Patient with Brugada Syndrome

A 35-year-old man experienced chest pain and a subsequent syncope attack at during the night. Ventricular fibrillation (VF) was documented, which was successfully defibrillated. The ST-segment of his 12-lead electrocardiogram (ECG) showed day-by-day variation, sometimes showing spontaneous coved-type elevation in V1 and V2. He was diagnosed as having Brugada syndrome, and an implantable cardioverter defibrillator was implanted. A coronary angiography was performed. During the procedure, the catheter was selectively inserted to the right ventricular (RV) branch of the right coronary artery (RCA) whereupon the ST-segment in V1 and V2 elevated rapidly, manifesting a coved-type Brugada ECG. The main RCA angiogram revealed the conus branch running to the RV outflow tract area, indicating that the ST-segment elevation was due to ischemia of the RV outflow tract area by transient occlusion of conus branch. The findings indicate that some patients with Brugada syndrome are specifically sensitive to ischemia in the RV outflow tract area, leading to manifestation of the ST-segment elevation in precordial ECG leads

Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation

Background: Dyspepsia (including upper abdominal pain, abdominal pain, abdominal discomfort, epigastric discomfort, and dyspepsia) is a symptom that is carefully monitored during dabigatran treatment. However, detailed information on dyspepsia, including onset, duration, severity, and use of drug treatment, has not yet been established in Japanese patients. Methods: We conducted a multi-center, prospective, open-label, randomized, and parallel-group-comparison observational study of 309 patients with non-valvular atrial fibrillation who had been newly prescribed dabigatran at 19 institutes in Japan. Gastrointestinal adverse events were evaluated using the Global Overall Severity (GOS) scale self-reports to describe symptoms and to assess frequency and severity of symptoms (Part 1). Thereafter, patients with a GOS score ≥3 were randomized to receive a 4-week course of a proton pump inhibitor, an H2-receptor antagonist or a gastric mucosal protective drug (Part 2). Results: The incidence of dyspepsia symptoms due to dabigatran was 17.2% (53/309, 95% confidence interval 13.1–21.8%), with 77% of events occurring within 10 days of initiation. Five patients discontinued the study because of dyspepsia. At the end of the observation period, the mean GOS score of those reporting dyspepsia was 3.5±1.7, with 11.3% (35/309) reporting a score ≥3. Substantial differences in the incidence of dyspepsia were observed between the study institutes (0–41%). In the multivariate regression analysis, no significant factor was found to affect incidence or severity of dyspepsia. The majority (83–100%) reported that symptoms improved with treatment (GOS score ≤2), and there was no significant difference between the three different treatment groups. Conclusions: The reported symptoms of dyspepsia were generally mild, but were moderate in approximately 10% of patients. Proton pump inhibitors, H2-receptor antagonists, and rebamipide seemed to be equally effective in relieving dabigatran-related dyspepsia (umin-CTR UMIN000007579)